Concepts (293)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunosuppressive Agents | 11 | 2018 | 168 | 2.760 |
Why?
|
| Dermatomyositis | 8 | 2017 | 19 | 2.390 |
Why?
|
| Keratosis | 10 | 2008 | 19 | 2.340 |
Why?
|
| Gingivitis | 3 | 2018 | 5 | 1.930 |
Why?
|
| Dermatologic Agents | 10 | 2017 | 208 | 1.760 |
Why?
|
| Keratosis, Actinic | 5 | 2014 | 18 | 1.620 |
Why?
|
| Aminoquinolines | 7 | 2010 | 16 | 1.570 |
Why?
|
| Photosensitivity Disorders | 7 | 2008 | 11 | 1.490 |
Why?
|
| Pyoderma Gangrenosum | 4 | 2019 | 12 | 1.470 |
Why?
|
| Fluorouracil | 8 | 2014 | 73 | 1.470 |
Why?
|
| Methotrexate | 9 | 2017 | 60 | 1.460 |
Why?
|
| Pemphigus | 3 | 2018 | 8 | 1.360 |
Why?
|
| Lichen Planus, Oral | 3 | 2018 | 11 | 1.330 |
Why?
|
| Pemphigoid, Benign Mucous Membrane | 2 | 2018 | 3 | 1.280 |
Why?
|
| Tacrolimus | 3 | 2018 | 44 | 1.260 |
Why?
|
| Skin Neoplasms | 5 | 2013 | 207 | 1.210 |
Why?
|
| Humans | 76 | 2019 | 29614 | 1.170 |
Why?
|
| Skin | 8 | 2019 | 205 | 1.140 |
Why?
|
| Wound Healing | 3 | 2019 | 186 | 1.100 |
Why?
|
| Skin Diseases | 3 | 2014 | 138 | 1.090 |
Why?
|
| Lupus Erythematosus, Cutaneous | 3 | 2019 | 13 | 0.910 |
Why?
|
| Adult | 32 | 2018 | 8535 | 0.800 |
Why?
|
| Hydroxychloroquine | 2 | 2019 | 9 | 0.800 |
Why?
|
| Morgellons Disease | 2 | 2018 | 3 | 0.790 |
Why?
|
| Male | 40 | 2019 | 18037 | 0.790 |
Why?
|
| Female | 42 | 2018 | 18414 | 0.790 |
Why?
|
| Antipsychotic Agents | 2 | 2018 | 26 | 0.780 |
Why?
|
| Prednisone | 6 | 2013 | 43 | 0.770 |
Why?
|
| Lichen Sclerosus et Atrophicus | 3 | 2017 | 7 | 0.750 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2014 | 149 | 0.740 |
Why?
|
| Treatment Outcome | 16 | 2018 | 3128 | 0.730 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2014 | 48 | 0.730 |
Why?
|
| Cryosurgery | 5 | 2014 | 19 | 0.730 |
Why?
|
| Scleroderma, Localized | 2 | 2017 | 5 | 0.720 |
Why?
|
| Stomatitis, Aphthous | 3 | 2005 | 4 | 0.700 |
Why?
|
| Trifluoperazine | 2 | 2018 | 3 | 0.670 |
Why?
|
| Glossitis, Benign Migratory | 1 | 2018 | 2 | 0.670 |
Why?
|
| Middle Aged | 28 | 2019 | 10954 | 0.650 |
Why?
|
| Diagnosis, Differential | 11 | 2018 | 494 | 0.650 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2019 | 43 | 0.640 |
Why?
|
| Mycophenolic Acid | 5 | 2015 | 28 | 0.600 |
Why?
|
| Administration, Topical | 9 | 2018 | 130 | 0.590 |
Why?
|
| Prognosis | 7 | 2018 | 1373 | 0.590 |
Why?
|
| Biopsy, Needle | 7 | 2018 | 90 | 0.570 |
Why?
|
| Skin Diseases, Vascular | 2 | 2018 | 9 | 0.570 |
Why?
|
| Vasculitis | 2 | 2018 | 23 | 0.570 |
Why?
|
| Facial Dermatoses | 2 | 2007 | 19 | 0.540 |
Why?
|
| Dermatitis, Atopic | 2 | 2017 | 86 | 0.530 |
Why?
|
| Aged, 80 and over | 13 | 2018 | 3771 | 0.530 |
Why?
|
| Drug Administration Schedule | 7 | 2018 | 247 | 0.530 |
Why?
|
| Neutrophils | 2 | 2014 | 102 | 0.520 |
Why?
|
| Aged | 23 | 2018 | 9617 | 0.510 |
Why?
|
| Clobetasol | 1 | 2015 | 25 | 0.510 |
Why?
|
| Behcet Syndrome | 3 | 2005 | 6 | 0.500 |
Why?
|
| Retrospective Studies | 10 | 2018 | 3145 | 0.490 |
Why?
|
| Colitis, Ulcerative | 1 | 2014 | 20 | 0.490 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2014 | 23 | 0.490 |
Why?
|
| Dermatitis | 4 | 2015 | 20 | 0.480 |
Why?
|
| Arthritis | 1 | 2014 | 38 | 0.480 |
Why?
|
| Precancerous Conditions | 2 | 2013 | 24 | 0.470 |
Why?
|
| Acne Vulgaris | 3 | 2010 | 93 | 0.450 |
Why?
|
| Severity of Illness Index | 7 | 2018 | 864 | 0.450 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2012 | 5 | 0.430 |
Why?
|
| Pemphigoid, Bullous | 1 | 2012 | 6 | 0.420 |
Why?
|
| Adolescent | 13 | 2018 | 3284 | 0.410 |
Why?
|
| Carcinoma | 1 | 2012 | 89 | 0.400 |
Why?
|
| Algorithms | 2 | 2012 | 468 | 0.390 |
Why?
|
| Administration, Cutaneous | 8 | 2014 | 107 | 0.380 |
Why?
|
| Immunohistochemistry | 6 | 2018 | 520 | 0.380 |
Why?
|
| Child | 10 | 2017 | 2234 | 0.380 |
Why?
|
| Hutchinson's Melanotic Freckle | 1 | 2010 | 2 | 0.370 |
Why?
|
| Antifungal Agents | 2 | 2007 | 34 | 0.350 |
Why?
|
| Ointments | 6 | 2010 | 23 | 0.350 |
Why?
|
| Skin Aging | 1 | 2009 | 8 | 0.350 |
Why?
|
| Combined Modality Therapy | 7 | 2014 | 525 | 0.340 |
Why?
|
| Child, Preschool | 7 | 2017 | 1172 | 0.340 |
Why?
|
| Ants | 1 | 2008 | 1 | 0.330 |
Why?
|
| Bedding and Linens | 1 | 2008 | 5 | 0.330 |
Why?
|
| Glomus Tumor | 1 | 2008 | 6 | 0.330 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2008 | 20 | 0.320 |
Why?
|
| Adrenal Cortex Hormones | 5 | 2015 | 148 | 0.320 |
Why?
|
| Double-Blind Method | 7 | 2010 | 507 | 0.320 |
Why?
|
| Tretinoin | 1 | 2008 | 34 | 0.320 |
Why?
|
| Alopecia | 1 | 2008 | 25 | 0.320 |
Why?
|
| Keratolytic Agents | 1 | 2008 | 29 | 0.320 |
Why?
|
| Curettage | 1 | 2007 | 9 | 0.300 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2007 | 27 | 0.300 |
Why?
|
| Scalp Dermatoses | 1 | 2007 | 14 | 0.290 |
Why?
|
| Anti-Bacterial Agents | 4 | 2018 | 286 | 0.290 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2018 | 91 | 0.290 |
Why?
|
| Tinea Pedis | 1 | 2006 | 6 | 0.290 |
Why?
|
| Physical Examination | 2 | 2018 | 83 | 0.280 |
Why?
|
| Disease Progression | 3 | 2018 | 576 | 0.280 |
Why?
|
| Medication Adherence | 2 | 2018 | 144 | 0.280 |
Why?
|
| Thiophenes | 1 | 2006 | 21 | 0.280 |
Why?
|
| Lupus Erythematosus, Systemic | 4 | 2014 | 145 | 0.280 |
Why?
|
| Quality of Life | 2 | 2017 | 833 | 0.280 |
Why?
|
| Cryotherapy | 2 | 2004 | 13 | 0.270 |
Why?
|
| Imidazoles | 1 | 2006 | 104 | 0.270 |
Why?
|
| Polychondritis, Relapsing | 1 | 2006 | 2 | 0.270 |
Why?
|
| Granuloma, Pyogenic | 1 | 2006 | 4 | 0.270 |
Why?
|
| Adjuvants, Immunologic | 2 | 2004 | 51 | 0.270 |
Why?
|
| Sunlight | 3 | 2013 | 17 | 0.260 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 840 | 0.250 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2005 | 50 | 0.250 |
Why?
|
| Cosmetic Techniques | 1 | 2004 | 11 | 0.250 |
Why?
|
| Recurrence | 4 | 2007 | 235 | 0.250 |
Why?
|
| Antineoplastic Agents | 2 | 2007 | 548 | 0.240 |
Why?
|
| Physical Therapy Modalities | 1 | 2004 | 60 | 0.240 |
Why?
|
| Immunoglobulin G | 1 | 2005 | 105 | 0.240 |
Why?
|
| Follow-Up Studies | 6 | 2018 | 2124 | 0.230 |
Why?
|
| United States | 5 | 2018 | 3695 | 0.230 |
Why?
|
| Drug Therapy, Combination | 5 | 2014 | 275 | 0.230 |
Why?
|
| Risk Assessment | 3 | 2018 | 1329 | 0.220 |
Why?
|
| Interferon Inducers | 1 | 2002 | 2 | 0.220 |
Why?
|
| Warts | 1 | 2002 | 2 | 0.220 |
Why?
|
| Salicylic Acid | 1 | 2002 | 6 | 0.220 |
Why?
|
| Microspheres | 3 | 2008 | 38 | 0.210 |
Why?
|
| Granuloma | 1 | 2002 | 13 | 0.210 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2002 | 34 | 0.210 |
Why?
|
| Azathioprine | 2 | 2015 | 8 | 0.210 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2002 | 5 | 0.210 |
Why?
|
| Clinical Trials as Topic | 3 | 2017 | 299 | 0.200 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 643 | 0.200 |
Why?
|
| Thalidomide | 4 | 2007 | 29 | 0.190 |
Why?
|
| Gels | 4 | 2010 | 33 | 0.190 |
Why?
|
| Naphthalenes | 2 | 2010 | 40 | 0.180 |
Why?
|
| Benzoyl Peroxide | 2 | 2010 | 19 | 0.180 |
Why?
|
| Patient Education as Topic | 2 | 2013 | 253 | 0.170 |
Why?
|
| Pruritus | 2 | 2012 | 58 | 0.170 |
Why?
|
| Wound Infection | 1 | 2018 | 11 | 0.160 |
Why?
|
| Leg | 1 | 2019 | 57 | 0.160 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2018 | 13 | 0.160 |
Why?
|
| Swine | 1 | 2019 | 204 | 0.160 |
Why?
|
| Remission Induction | 3 | 2013 | 78 | 0.150 |
Why?
|
| Neoplasm Staging | 2 | 2010 | 441 | 0.150 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 152 | 0.150 |
Why?
|
| Drug Resistance | 1 | 2017 | 37 | 0.150 |
Why?
|
| Steroids | 1 | 2017 | 36 | 0.150 |
Why?
|
| Patient Compliance | 2 | 2013 | 213 | 0.150 |
Why?
|
| Lichen Planus | 1 | 2017 | 6 | 0.150 |
Why?
|
| Nausea | 1 | 2017 | 49 | 0.150 |
Why?
|
| Urinary Bladder | 1 | 2019 | 165 | 0.150 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 169 | 0.140 |
Why?
|
| Mother-Child Relations | 1 | 2017 | 15 | 0.140 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 150 | 0.140 |
Why?
|
| Databases, Factual | 1 | 2018 | 333 | 0.140 |
Why?
|
| Darier Disease | 1 | 2016 | 2 | 0.140 |
Why?
|
| Young Adult | 3 | 2018 | 2432 | 0.140 |
Why?
|
| Glucocorticoids | 2 | 2015 | 149 | 0.140 |
Why?
|
| Activities of Daily Living | 1 | 2017 | 242 | 0.130 |
Why?
|
| Stress, Psychological | 1 | 2017 | 211 | 0.130 |
Why?
|
| Panniculitis, Lupus Erythematosus | 1 | 2014 | 5 | 0.120 |
Why?
|
| Syndrome | 1 | 2014 | 66 | 0.120 |
Why?
|
| Lupus Erythematosus, Discoid | 1 | 2014 | 8 | 0.120 |
Why?
|
| Retinal Vasculitis | 1 | 2014 | 1 | 0.120 |
Why?
|
| Sweet Syndrome | 1 | 2014 | 7 | 0.120 |
Why?
|
| Prospective Studies | 2 | 2012 | 2050 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2015 | 376 | 0.110 |
Why?
|
| Cohort Studies | 1 | 2018 | 1708 | 0.110 |
Why?
|
| Nurse Practitioners | 1 | 2013 | 10 | 0.110 |
Why?
|
| Animals | 2 | 2019 | 7341 | 0.110 |
Why?
|
| International Agencies | 1 | 2012 | 6 | 0.110 |
Why?
|
| Singapore | 1 | 2012 | 10 | 0.110 |
Why?
|
| Calcium Compounds | 1 | 2012 | 8 | 0.110 |
Why?
|
| Diphosphonates | 1 | 2012 | 9 | 0.110 |
Why?
|
| Oxides | 1 | 2012 | 15 | 0.110 |
Why?
|
| Bone Density Conservation Agents | 1 | 2012 | 20 | 0.110 |
Why?
|
| Erythema | 1 | 2012 | 27 | 0.100 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2012 | 110 | 0.100 |
Why?
|
| Physician Assistants | 1 | 2013 | 41 | 0.100 |
Why?
|
| Pilot Projects | 2 | 2018 | 489 | 0.100 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2011 | 6 | 0.100 |
Why?
|
| Pityriasis Lichenoides | 1 | 2011 | 3 | 0.100 |
Why?
|
| Immunosuppression | 1 | 2012 | 80 | 0.100 |
Why?
|
| Skin Ulcer | 1 | 2011 | 10 | 0.100 |
Why?
|
| Patient Care Team | 1 | 2013 | 124 | 0.100 |
Why?
|
| Herpes Simplex | 1 | 2011 | 12 | 0.100 |
Why?
|
| Blood Vessels | 1 | 2012 | 47 | 0.100 |
Why?
|
| Muscle Strength | 1 | 2012 | 146 | 0.100 |
Why?
|
| Risk Factors | 3 | 2014 | 3612 | 0.100 |
Why?
|
| Dietary Supplements | 1 | 2012 | 172 | 0.100 |
Why?
|
| Vitamin D | 1 | 2012 | 175 | 0.090 |
Why?
|
| Cross-Over Studies | 1 | 2010 | 95 | 0.090 |
Why?
|
| Dermoscopy | 1 | 2010 | 8 | 0.090 |
Why?
|
| Doxycycline | 1 | 2010 | 25 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2010 | 471 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 71 | 0.090 |
Why?
|
| Socioeconomic Factors | 1 | 2010 | 397 | 0.080 |
Why?
|
| Emulsions | 2 | 2007 | 7 | 0.080 |
Why?
|
| Mastocytosis, Cutaneous | 1 | 2008 | 3 | 0.080 |
Why?
|
| Pedigree | 1 | 2008 | 135 | 0.080 |
Why?
|
| Alkylating Agents | 1 | 2008 | 5 | 0.080 |
Why?
|
| Drug Carriers | 1 | 2008 | 16 | 0.080 |
Why?
|
| Plasma Exchange | 1 | 2008 | 10 | 0.080 |
Why?
|
| Cyclosporine | 1 | 2008 | 34 | 0.080 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2008 | 21 | 0.080 |
Why?
|
| Mouth Mucosa | 1 | 2008 | 29 | 0.080 |
Why?
|
| Acute Disease | 1 | 2008 | 239 | 0.080 |
Why?
|
| European Continental Ancestry Group | 1 | 2012 | 1132 | 0.080 |
Why?
|
| Administration, Oral | 4 | 2010 | 172 | 0.080 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2007 | 27 | 0.080 |
Why?
|
| Fatigue | 1 | 2007 | 71 | 0.070 |
Why?
|
| Dermatomycoses | 1 | 2007 | 6 | 0.070 |
Why?
|
| Headache | 1 | 2007 | 74 | 0.070 |
Why?
|
| Cephalexin | 1 | 2006 | 1 | 0.070 |
Why?
|
| Skin Diseases, Infectious | 1 | 2006 | 3 | 0.070 |
Why?
|
| Staphylococcal Skin Infections | 1 | 2006 | 4 | 0.070 |
Why?
|
| Streptococcus pyogenes | 1 | 2006 | 17 | 0.070 |
Why?
|
| Streptococcal Infections | 1 | 2006 | 20 | 0.070 |
Why?
|
| Lipids | 1 | 2007 | 215 | 0.070 |
Why?
|
| Exercise Therapy | 1 | 2008 | 238 | 0.070 |
Why?
|
| Fingers | 1 | 2006 | 57 | 0.070 |
Why?
|
| Therapeutic Equivalency | 1 | 2004 | 2 | 0.060 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2005 | 7 | 0.060 |
Why?
|
| Lichenoid Eruptions | 1 | 2004 | 1 | 0.060 |
Why?
|
| Fluocinonide | 2 | 2018 | 11 | 0.060 |
Why?
|
| Scleroderma, Systemic | 1 | 2004 | 7 | 0.060 |
Why?
|
| Sunscreening Agents | 1 | 2004 | 11 | 0.060 |
Why?
|
| Diclofenac | 1 | 2004 | 1 | 0.060 |
Why?
|
| Aminolevulinic Acid | 1 | 2004 | 6 | 0.060 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2004 | 11 | 0.060 |
Why?
|
| Ultraviolet Rays | 1 | 2004 | 46 | 0.060 |
Why?
|
| Photosensitizing Agents | 1 | 2004 | 19 | 0.060 |
Why?
|
| Photochemotherapy | 1 | 2004 | 17 | 0.060 |
Why?
|
| Oral Ulcer | 1 | 2003 | 5 | 0.060 |
Why?
|
| Ulcer | 1 | 2003 | 3 | 0.060 |
Why?
|
| Genital Diseases, Female | 1 | 2003 | 5 | 0.060 |
Why?
|
| Patient Selection | 1 | 2004 | 257 | 0.060 |
Why?
|
| Least-Squares Analysis | 1 | 2002 | 29 | 0.050 |
Why?
|
| Heel | 1 | 2002 | 6 | 0.050 |
Why?
|
| Toes | 1 | 2002 | 16 | 0.050 |
Why?
|
| Age of Onset | 1 | 2003 | 96 | 0.050 |
Why?
|
| Life Style | 1 | 2004 | 372 | 0.050 |
Why?
|
| Hand | 1 | 2002 | 63 | 0.050 |
Why?
|
| Infant | 3 | 2011 | 976 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2002 | 188 | 0.050 |
Why?
|
| Age Distribution | 1 | 2002 | 199 | 0.050 |
Why?
|
| Psoriasis | 1 | 2005 | 334 | 0.050 |
Why?
|
| Drug Combinations | 2 | 2010 | 86 | 0.050 |
Why?
|
| Risperidone | 1 | 2018 | 3 | 0.040 |
Why?
|
| Incidence | 1 | 2002 | 1128 | 0.040 |
Why?
|
| Consensus | 1 | 2018 | 70 | 0.040 |
Why?
|
| Terminology as Topic | 1 | 2018 | 63 | 0.040 |
Why?
|
| Wrist | 1 | 2017 | 41 | 0.040 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2016 | 7 | 0.030 |
Why?
|
| Nails | 1 | 2016 | 6 | 0.030 |
Why?
|
| Disease Management | 1 | 2016 | 114 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2014 | 73 | 0.030 |
Why?
|
| Ophthalmoscopy | 1 | 2014 | 9 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2014 | 40 | 0.030 |
Why?
|
| Outpatients | 1 | 2014 | 49 | 0.030 |
Why?
|
| Vision Disorders | 1 | 2014 | 20 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2014 | 98 | 0.030 |
Why?
|
| Calcinosis | 1 | 2014 | 143 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2014 | 178 | 0.030 |
Why?
|
| Antibodies, Antinuclear | 1 | 2012 | 18 | 0.030 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2012 | 7 | 0.030 |
Why?
|
| Lupus Nephritis | 1 | 2012 | 30 | 0.030 |
Why?
|
| Vancomycin | 1 | 2011 | 19 | 0.030 |
Why?
|
| Clindamycin | 1 | 2011 | 18 | 0.030 |
Why?
|
| Biopsy | 1 | 2012 | 243 | 0.020 |
Why?
|
| DNA | 1 | 2012 | 209 | 0.020 |
Why?
|
| Mechlorethamine | 1 | 2010 | 1 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 533 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 1398 | 0.020 |
Why?
|
| Silver Sulfadiazine | 1 | 2008 | 4 | 0.020 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2008 | 13 | 0.020 |
Why?
|
| Mast Cells | 1 | 2008 | 17 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2008 | 24 | 0.020 |
Why?
|
| Hypopigmentation | 1 | 2008 | 7 | 0.020 |
Why?
|
| Lip | 1 | 2008 | 8 | 0.020 |
Why?
|
| Time Factors | 1 | 2013 | 2014 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2007 | 82 | 0.020 |
Why?
|
| Intertrigo | 1 | 2007 | 1 | 0.020 |
Why?
|
| Gram-Positive Bacteria | 1 | 2007 | 2 | 0.020 |
Why?
|
| Mitosporic Fungi | 1 | 2007 | 2 | 0.020 |
Why?
|
| Dermatitis, Seborrheic | 1 | 2007 | 4 | 0.020 |
Why?
|
| Tinea | 1 | 2007 | 4 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2007 | 55 | 0.020 |
Why?
|
| Retinoids | 1 | 2007 | 41 | 0.020 |
Why?
|
| Methicillin Resistance | 1 | 2006 | 13 | 0.020 |
Why?
|
| Diterpenes | 1 | 2006 | 15 | 0.020 |
Why?
|
| Staphylococcus aureus | 1 | 2006 | 45 | 0.020 |
Why?
|
| Macrophages | 1 | 2007 | 188 | 0.020 |
Why?
|
| Cytokines | 1 | 2007 | 244 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2007 | 796 | 0.020 |
Why?
|
| Dermatology | 1 | 2007 | 154 | 0.020 |
Why?
|
| Myxedema | 1 | 2004 | 3 | 0.020 |
Why?
|
| Paraproteinemias | 1 | 2004 | 3 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2006 | 605 | 0.020 |
Why?
|
| Inflammation | 1 | 2007 | 511 | 0.010 |
Why?
|
| Prevalence | 1 | 2004 | 912 | 0.010 |
Why?
|